S
Scott Pesiridis
Researcher at GlaxoSmithKline
Publications - 3
Citations - 916
Scott Pesiridis is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Innate immune system & Cytotoxic T cell. The author has an hindex of 3, co-authored 3 publications receiving 378 citations.
Papers
More filters
Journal ArticleDOI
DNA sensing by the cGAS–STING pathway in health and disease
TL;DR: The cGAS–STING pathway forms a major DNA-sensing mechanism in mammalian cells and emerging evidence of its role in monogenic inflammatory diseases and cancer and new therapeutic opportunities is highlighted.
Journal ArticleDOI
Succination inactivates gasdermin D and blocks pyroptosis
Fiachra Humphries,Liraz Shmuel-Galia,Natália Ketelut-Carneiro,Sheng Li,Bingwei Wang,Venkatesh V. Nemmara,Ruth Wilson,Zhaozhao Jiang,Farnaz Khalighinejad,Khaja Muneeruddin,Scott A. Shaffer,Ranjan Dutta,Carolina Ionete,Scott Pesiridis,Shuo Yang,Paul R. Thompson,Katherine A. Fitzgerald +16 more
TL;DR: In mice, the administration of DMF protects against lipopolysaccharide shock and alleviates familial Mediterranean fever and experimental autoimmune encephalitis by targeting GSDMD, revealing a mechanism of action for fumarate-based therapeutics that include DMF, for the treatment of multiple sclerosis.
Proceedings ArticleDOI
Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity
Jingsong Yang,Michael Adam,Jim Clemens,Katrina L. Creech,Jess Schneck,Kishore Pasikanti,Jean-Luc Tran,Devika Joglekar,Chris Hopson,Scott Pesiridis,Ramanjulu Joshi M,Yiqian Lian,Jerry L. Adams,James F. Smothers,Axel Hoos +14 more
TL;DR: Significant evidence of the development of anti-tumor adaptive immune response comes from the observation that the efficacy of GSK532 was significantly attenuated when CD8+ T cells were depleted in the murine model.